scholarly journals Study of the Osteoporotic Changes in Postmenopausal Women with Type-2 Diabetes Mellitus

2017 ◽  
Vol 18 (1) ◽  
pp. 21-26
Author(s):  
Ayesha Jahan ◽  
Rokeya Begum ◽  
Khaled Bin Shamsuddin
Keyword(s):  
Diabetes Mellitus ◽  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Femoral Neck ◽  
Postmenopausal Women ◽  
Mineral Density ◽  
Group I ◽  
Group Ii

Introduction: Osteoporosis and Diabetes Mellitus (DM) are common medical conditions in the society with an increasing prevalence in elderly people. Osteoporosis is more common in female than male and postmenopausal women are vulnerable to it.   Objective: The aim of this study was to verify the effect of type-2 diabetes mellitus on bone mineral density in postmenopausal women and, thereby, to evaluate the risk of osteoporosis in them.   Materials and Methods: This cross-sectional study was carried out at National institute of Nuclear Medicine and Allied Sciences (NINMAS), BSMMU campus, Shahbagh, Dhaka, over a period of one year. 175 postmenopausal women were enrolled as study subjects, among them 72 (41.10%) were diabetic and rest 103 (59.90%) were nondiabetic and they were assigned as Group-I and Group-II respectively. The bone mineral density (BMD) was measured by central DEXA device at lumbar spines and left femoral neck of each study subject.   Results: The mean (±SD) ages of group-I and group-II were 58.79 (±8.06) and 58.27 (±8.39) respectively with an age range of 45 to 75 years in both cases. A total of 30 (41.66%) patients in diabetic group (group-I) and 40 (38.83%) patients in non-diabetic (group-II) had osteoporosis at lumbar spines. On the other hand, 40 (56.94%) patients in group-I and 58 (56.31%) patients in group-II had osteoporosis at femoral neck. The Odds Ratios of osteoporosis for lumbar spines and femoral. neck were 1.125 and 1.026 respectively. The differences of frequencies of osteoporosis between group-I and group-II were not statistically significant at any anatomical site and the association between osteoporosis and type-2 diabetes mellitus was not significant. According to Odds Ratio type-2 diabetes mellitus was not a risk factor for developing osteoporosis in postmenopausal women.   Conclusion: Postmenopausal women are prone to develop osteoporosis and type-2 diabetes mellitus may have adverse influence on osteoporosis, which was supported by few previous studies. This study could not establish any significant effect of type-2 diabetes mellitus on osteoporosis in postmenopausal women.Bangladesh J. Nuclear Med. 18(1): 21-26, January 2015

scholarly journals Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Ting-ting Cai ◽  
Hui-qin Li ◽  
Lan-lan Jiang ◽  
Hui-ying Wang ◽  
Meng-hui Luo ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Placebo Group ◽  
Femoral Neck ◽  
Insulin Glargine ◽  
Mineral Density ◽  
Total Hip

Introduction. Hypoglycemic drugs affect the bone quality and the risk of fractures in patients with type 2 diabetes mellitus (T2DM). We aimed to investigate the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and insulin on bone mineral density (BMD) in T2DM. Methods. In this single-blinded study, a total of 65 patients with T2DM were randomly assigned into four groups for 52 weeks: the exenatide group ( n = 19 ), dulaglutide group ( n = 19 ), insulin glargine group ( n = 10 ), and placebo ( n = 17 ). General clinical data were collected, and BMD was measured by dual-energy X-ray absorptiometry. Results. Compared with baseline, the glycosylated hemoglobin (HbA1c) decreased significantly in the exenatide ( 8.11 ± 0.24 % vs. 7.40 ± 0.16 % , P = 0.007 ), dulaglutide ( 8.77 ± 0.37 % vs. 7.06 ± 0.28 % , P < 0.001 ), and insulin glargine ( 8.57 ± 0.24 % vs. 7.23 ± 0.25 % , P < 0.001 ) groups after treatment. In the exenatide group, the BMD of the total hip increased. In the dulaglutide group, only the BMD of the femoral neck decreased ( P = 0.027 ), but the magnitude of decrease was less than that in the placebo group; the BMD of L1-L4, femoral neck, and total hip decreased significantly ( P < 0.05 ) in the placebo group, while in the insulin glargine group, the BMD of L2, L4, and L1-4 increased ( P < 0.05 ). Compared with the placebo group, the BMD of the femoral neck and total hip in the exenatide group and the insulin glargine group were increased significantly ( P < 0.05 ); compared with the exenatide group, the BMD of L4 in the insulin glargine group was also increased ( P = 0.001 ). Conclusions. Compared with the placebo, GLP-1RAs demonstrated an increase of BMD at multiple sites of the body after treatment, which may not exacerbate the consequences of bone fragility. Therefore, GLP-1RAs might be considered for patients with T2DM. This trial is registered with ClinicalTrials.gov NCT01648582.

scholarly journals Increased bone mineral density in postmenopausal women with type 2 diabetes mellitus

2008 ◽  
Vol 28 (2) ◽  
pp. 102-104 ◽  
Author(s):  
Irzal Hadzibegovic ◽  
Blazenka Miskic ◽  
Vesna Cosic ◽  
Deiti Prvulovic ◽  
Dragica Bistrovic
Keyword(s):  
Diabetes Mellitus ◽  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Mineral Density
Sign in / Sign up

Export Citation Format

Share Document